Official announcement released by Government of India via Press Information Bureau (PIB). Under the new framework, trade margins on these medicines will be limited to 30% of the MRP, extending the price protection to medicines that had higher higher mark-ups. The Centre has capped trade margins on all non-scheduled anti-cancer drugs at 30% of MRP, a move expected to reduce medicine prices and save cancer patients around Rs 2,500 crore annually.